Open Access

Lysophosphatidic acid protects cervical cancer HeLa cells from apoptosis induced by doxorubicin hydrochloride

  • Authors:
    • Xibo Wang
    • Haihua Wang
    • Xiaoxiao Mou
    • Yilin Xu
    • Wenbo Han
    • Aimin Huang
    • Yanwei Li
    • Hui Jiang
    • Xiaoyun Yang
    • Zhenbo Hu
  • View Affiliations

  • Published online on: June 17, 2022     https://doi.org/10.3892/ol.2022.13387
  • Article Number: 267
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cervical cancer is one of the most common types of gynecological tumors. Lysophosphatidic acid (LPA), as a bioactive lipid medium, plays an important role in numerous physiological and pathophysiological processes, including the stimulation of cell migration and tumor cell invasion. LPA is increased in the plasma of patients with cervical cancer. Doxorubicin hydrochloride (DOX) is used as a first‑line drug in the treatment of cervical cancer in clinics, however, the effect and molecular mechanism of LPA on DOX‑induced apoptosis in cervical cancer cells remain unclear. Therefore, the present study aimed to explore the effect and underlying molecular mechanism of LPA on DOX‑induced apoptosis in cervical cancer cells. HeLa cells were treated as a control group or with LPA (10 µmol/l), DOX (4 µmol/l) or LPA (10 µmol/l) + DOX (4 µmol/l) for 24 h. Using transmission electron microscopy the results demonstrated that LPA reduced cell death and the degree of chromatin aggregation in DOX‑induced HeLa cells. Reverse transcription‑quantitative PCR demonstrated that LPA significantly downregulated caspase‑3 mRNA expression levels in DOX‑induced HeLa cells. Moreover, western blotting demonstrated that LPA significantly reduced caspase‑3 and cleaved caspase‑3 protein expression levels in DOX‑induced HeLa, C33A and SiHa cells. Furthermore, flow cytometry demonstrated that LPA may prevent apoptosis in DOX‑induced HeLa cells (P<0.05). Using dichloro‑dihydro‑fluorescein diacetate assay, it was demonstrated that LPA significantly reduced the intracellular ROS levels induced by DOX. In summary, the present study indicated that LPA may protect HeLa cells from apoptosis induced by DOX. These findings have provided experimental evidence that LPA may be a potential therapeutic target for the treatment of cervical cancer.
View Figures
View References

Related Articles

Journal Cover

August-2022
Volume 24 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang X, Wang H, Mou X, Xu Y, Han W, Huang A, Li Y, Jiang H, Yang X, Hu Z, Hu Z, et al: Lysophosphatidic acid protects cervical cancer HeLa cells from apoptosis induced by doxorubicin hydrochloride. Oncol Lett 24: 267, 2022
APA
Wang, X., Wang, H., Mou, X., Xu, Y., Han, W., Huang, A. ... Hu, Z. (2022). Lysophosphatidic acid protects cervical cancer HeLa cells from apoptosis induced by doxorubicin hydrochloride. Oncology Letters, 24, 267. https://doi.org/10.3892/ol.2022.13387
MLA
Wang, X., Wang, H., Mou, X., Xu, Y., Han, W., Huang, A., Li, Y., Jiang, H., Yang, X., Hu, Z."Lysophosphatidic acid protects cervical cancer HeLa cells from apoptosis induced by doxorubicin hydrochloride". Oncology Letters 24.2 (2022): 267.
Chicago
Wang, X., Wang, H., Mou, X., Xu, Y., Han, W., Huang, A., Li, Y., Jiang, H., Yang, X., Hu, Z."Lysophosphatidic acid protects cervical cancer HeLa cells from apoptosis induced by doxorubicin hydrochloride". Oncology Letters 24, no. 2 (2022): 267. https://doi.org/10.3892/ol.2022.13387